Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OMER

OMER - Omeros Corp Stock Price, Fair Value and News

$11.81-0.86 (-6.79%)
Market Closed

4/100

OMER

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

OMER

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$9.54

Target 3M

$10.74

Target 6M

$10.14

OMER Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OMER Price Action

Last 7 days

-2.2%

Last 30 days

-28.7%

Last 90 days

57.1%

Trailing 12 Months

31.8%

OMER RSI Chart

OMER Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OMER Valuation

Market Cap

837.3M

Price/Earnings (Trailing)

-6.91

Price/Sales (Trailing)

160.69

EV/EBITDA

-4.1

Price/Free Cashflow

-7.95

OMER Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$9.54

Target 3M

$10.74

Target 6M

$10.14

OMER Fundamentals

OMER Revenue

Revenue (TTM)

5.2M

Rev. Growth (Yr)

-73.74%

Rev. Growth (Qtr)

-50.36%

OMER Earnings

Earnings (TTM)

-121.2M

Earnings Growth (Yr)

4.08%

Earnings Growth (Qtr)

-21.61%

OMER Profitability

EBT Margin

-3493.17%

Return on Equity

54.95%

Return on Assets

-65.24%

Free Cashflow Yield

-12.58%

OMER Investor Care

Shares Dilution (1Y)

22.35%

Diluted EPS (TTM)

-2.04

OMER Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20258.9M6.9M5.2M0
202415.8M14.5M12.4M11.3M
20237.4M11.4M14.9M16.3M
20222.5M03.3M4.1M
202171.3M86.6M44.2M1.7M
2020113.6M100.3M96.6M73.8M
201950.1M75.2M100.4M111.8M
201856.1M47.3M38.6M29.9M
201746.5M53.6M64.0M64.8M
201620.4M27.2M35.2M41.4M
2015827.0K4.0M7.0M13.5M
2014605.0K510.0K528.0K539.0K
20135.6M4.2M3.0M1.6M
20124.8M5.2M5.6M6.0M
20113.0M3.6M4.4M4.5M
2010001.9M2.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Omeros Corp

OMER
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEomeros.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES196

Omeros Corp Frequently Asked Questions

OMER is the stock ticker symbol of Omeros Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Omeros Corp is 837.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OMER's fair value in chart for subscribers.

The fair value guage provides a quick view whether OMER is over valued or under valued. Whether Omeros Corp is cheap or expensive depends on the assumptions which impact Omeros Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMER.

As of Wed Jan 28 2026, OMER's PE ratio (Price to Earnings) is -6.91 and Price to Sales (PS) ratio is 160.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMER PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Omeros Corp has provided 0.009 (multiply by 100 for percentage) rate of return.